A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Press release
Astellas Receives “2021 Award for Excellence in Corporate Disclosure” from the Securities Analysts Association of Japan
Oct 20, 2021

TOKYO, October 20, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the company has ranked first in the pharmaceuticals sector for the “2021 Award for Excellence in Corporate Disclosure” granted by the Securities Analysts Association of Japan (SAAJ) to promote the quality and fairness of corporate disclosure.

Astellas was highly evaluated mainly in the following areas:

  • Significant improvement in IR stance, with the top management’s proactive information dissemination and engagement in dialogue  
  • IR group has sufficient accumulated information, and securities analysts and institutional investors are having a useful dialogue with IR personnel
  • Announcement of a medium-term plan (“Corporate Strategic Plan 2021” *1), a full explanation of subsequent progress with concrete measures for achievement, and a capital allocation policy
  • Stock market needs are incorporated into the disclosure materials of the medium-term plan

Astellas’ raison d'être is “to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.” With research and development at the heart of the company, Astellas constantly takes on challenges to deliver innovative new drugs and medical solutions by leveraging its core capabilities. In addition, Astellas aims to sustainably enhance its enterprise value by being chosen and trusted by all the stakeholders including customers, shareholders, employees and community.

Upon receiving the award, Kenji Yasukawa, President and CEO, Astellas, stated as follows:
“Our disclosure philosophy is to make our products on the market and the clinical trial results known in a timely and appropriate manner, as well as proactively explain to the stakeholders not only the features of the projects under research and development, but also the potential impact on society when they are launched. In addition, we strive to make the opportunity to provide information flexibly in line with the requests and needs of the stakeholders so that we do not unilaterally disseminate information. As a result of these efforts, we believe that we were able to improve the perception of our advocacy activities and our disclosure philosophy, which led to this recognition.”

Astellas will continue to disclose information in a timely, appropriate, and fair manner, as well as proactively engage in dialogue with stakeholders and further improve transparency. Astellas will continue to strive to enhance and improve the quality of its disclosure.

Excellence in Corporate Disclosure

For details on regarding the  “Excellence in Corporate Disclosure,” please refer to the website of the SAAJ (https://www.saa.or.jp/english/research/disclosure.html).

 

*1: Astellas Corporate website “Corporate Strategic Plan 2021”. Available at:
https://www.astellas.com/en/about/csp2021

Click below for a copy of the full press release

1 /